FDA inspection
GlaxoSmithKline Biologicals: FDA inspection ending Aug 5, 2025
FDA inspection 1280789 · Singapore
Key facts
| Inspection ID | 1280789 |
|---|---|
| Firm | GlaxoSmithKline Biologicals |
| FEI number | 3016007176 |
| Address | 10 Tuas South Avenue 8 |
| City | Singapore |
| Fiscal year | 2025 |
| Inspection end date | Aug 5, 2025 |
| Project area | Vaccine, Allergenic, and Live Biotherapeutic Products |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data